IRadimed Corporation
NASDAQ:IRMDMedical - Devices
+$0.67 today
- Market cap
- $1.05B
- Beta
- 0.92
- P/E (TTM)
- 49.7
- EPS (TTM)
- $1.85
- Dividend yield
- 1.35%
Volume 0.08M
Average 0.12M
IRMD Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
IRadimed CorporationNASDAQ: IRMD
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$56.37M, compared with -$50.27M a year earlier.
Context
- Net debt amounted to 49.3% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -12.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (51.16M) USD
- Year-over-year change
- +1.8%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (51.16M) | +1.8% |
| FY2024 | 2024-12-31 | (52.08M) | -9.1% |
| FY2023 | 2023-12-31 | (47.72M) | +14.4% |
| FY2022 | 2022-12-31 | (55.76M) | +6.3% |
| FY2021 | 2021-12-31 | (59.52M) | — |
Net Debt vs competitors
How IRMD compares with its peers on the latest reported figures
- IRMD's Mar 2026 net debt of -$56.37M is the 7th highest of the 11 companies compared; the peer median is $180.34M.
- Its year-over-year change of -12.1% is the 8th highest of 11, against a peer median of -3.3%.
- Net debt amounts to 49.3% of total assets for IRMD, versus a peer median of 49.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CTEVClaritev Corporation | Mar 2026 | $4.59B | -0.5% | +1.2% | 94.8% |
| Apr 2026 | $1.95B | -4.7% | -7.7% | 44.1% | |
| Mar 2026 | $1.8B | +1.3% | +15.3% | 50.4% | |
| Mar 2026 | $555.41M | +26.3% | +12.7% | 48.2% | |
| Mar 2026 | $305.64M | +27.2% | — | 15.1% | |
| Mar 2026 | $55.05M | -3.2% | -24.9% | 3.0% | |
| Mar 2026 | -$56.37M | -12.1% | — | 49.3% | |
| Mar 2026 | -$142.18M | -62.0% | — | 46.1% | |
| Sep 2026 | -$309.42M | -803.0% | -14.9% | 56.2% | |
| Mar 2026 | -$389.47M | -177.5% | — | 51.9% | |
| Mar 2026 | -$823.24M | -3.4% | — | 70.0% | |
| Peer median (excluding IRMD) | $180.34M | -3.3% | -3.2% | 49.3% | |
Competitors are the stored peer set for IRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 62M | 57.96M | 49.76M | 52.23M | 51.16M |
| Short-term Investments | 501.86K | 0 | 0 | 0 | 0 |
| Net Receivables | 5.14M | 13.27M | 12.22M | 10.56M | 13.67M |
| Inventory | 4.3M | 5.37M | 12.82M | 10.4M | 11.62M |
| Other Current Assets | 1M | 630.96K | 1.19M | 2.05M | 4.76M |
| Total Current Assets | 76.24M | 77.49M | 76M | 75.24M | 81.2M |
| Property, Plant & Equipment (Net) | 4.55M | 4.61M | 11.33M | 16.97M | 23.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.12M | 2.07M | 2.52M | 3.1M | 3.38M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 765.1K | 700.87K | 2.12M | 2.82M | 94K |
| Other Non-current Assets | 201.33K | 648.67K | 181.45K | 198.91K | 239K |
| Total Non-current Assets | 6.64M | 8.02M | 16.15M | 23.08M | 27.57M |
| Total Assets | 82.88M | 85.51M | 92.16M | 98.33M | 108.78M |
| Account Payables | 782.9K | 1.8M | 1.86M | 1.9M | 1.82M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 140.32K | 121.92K | 353.28K | 163K | 0 |
| Deferred Revenue | 2.55M | 3.37M | 2.57M | 2.26M | 2.87M |
| Other Current Liabilities | 255.32K | 94.03K | 367.46K | 268.27K | 457K |
| Total Current Liabilities | 6.82M | 8.55M | 16.33M | 8.51M | 10.18M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.68M | 1.38M | 2.79M | 2.99M | 3.98M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 3.88M | 3.29M | 4.41M | 2.99M | 3.98M |
| Total Liabilities | 10.71M | 11.84M | 20.74M | 11.51M | 14.16M |
| Common Stock | 1.25K | 1.26K | 1.27K | 1.27K | 1K |
| Retained Earnings | 46.99M | 47.26M | 43.26M | 56.79M | 64.23M |
| Accumulated OCI | 17.01K | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 72.17M | 73.67M | 71.42M | 86.82M | 94.62M |
| Total Debt | 2.48M | 2.21M | 2.04M | 154.69K | 0 |
| Net Debt | (59.52M) | (55.76M) | (47.72M) | (52.08M) | (51.16M) |
IRadimed Corporation
NASDAQ:IRMD
Intrinsic Alpha fair value
Locked
Current Price
$82.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.